Patent Ductus Arteriosus: Are Current Neonatal Treatment Options Better or Worse Than No Treatment at All?

被引:189
|
作者
Clyman, Ronald I. [1 ,2 ]
Couto, James [3 ]
Murphy, Gail M. [4 ]
机构
[1] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA
[3] Amer Acad Pediat, Div Hosp & Surg Serv, Elk Grove Village, IL USA
[4] Neonatal Res & Technol Assessment Inc, Burlington, VT USA
关键词
ibuprofen; indomethacin; ligation; PDA management; CEREBRAL-BLOOD-FLOW; BIRTH-WEIGHT INFANTS; PRETERM INFANTS; PREMATURE-INFANTS; RISK-FACTORS; INTRAVENTRICULAR HEMORRHAGE; INDOMETHACIN THERAPY; ECHOCARDIOGRAPHIC PREDICTION; BRONCHOPULMONARY DYSPLASIA; PROPHYLACTIC INDOMETHACIN;
D O I
10.1053/j.semperi.2011.09.022
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Although a moderate-sized patent ductus arteriosus (PDA) needs to be closed by the time a child is 1-2 years old, there is great uncertainty about whether it needs to be closed during the neonatal period. Although 95% of neonatologists believe that a moderate-sized PDA should be closed if it persists in infants (born before 28 weeks) who still require mechanical ventilation, the number of neonatologists who treat a PDA when it occurs in infants who do not require mechanical ventilation varies widely. Both the high likelihood of spontaneous ductus closure and the absence of randomized controlled trials, specifically addressing the risks and benefits of neonatal ductus closure, add to the current uncertainty. New information suggests that early pharmacologic treatment has several important short-term benefits for the preterm newborn. By contrast, ductus ligation, while eliminating the detrimental effects of a PDA on lung development, may create its own set of morbidities that counteract many of the benefits derived from ductus closure. Semin Perinatol 36:123-129 (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 50 条
  • [21] Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions
    Rostas, Sara E.
    McPherson, Christopher C.
    CURRENT PEDIATRIC REVIEWS, 2016, 12 (02) : 110 - 119
  • [22] Does crossover treatment of control subjects invalidate results of randomized trials of patent ductus arteriosus treatment?
    Sankar, Meera N.
    Benitz, William E.
    JOURNAL OF PERINATOLOGY, 2020, 40 (12) : 1863 - 1870
  • [23] Worse Outcomes of Early Targeted Ibuprofen Treatment Compared to Expectant Management of Patent Ductus Arteriosus in Extremely Premature Infants
    Termerova, Jana
    Kubena, Ales Antonin
    Paslerova, Rachel
    Liska, Karel
    JOURNAL OF CLINICAL NEONATOLOGY, 2021, 10 (04) : 209 - 215
  • [24] Cerebral Oxygenation during Different Treatment Strategies for a Patent Ductus Arteriosus
    Chock, Valerie Y.
    Ramamoorthy, Chandra
    Van Meurs, Krisa P.
    NEONATOLOGY, 2011, 100 (03) : 233 - 240
  • [25] Ibuprofen treatment after the first days of life in preterm neonates with patent ductus arteriosus
    de Klerk, Johan C. A.
    van Paassen, Nanda
    van Beynum, Ingrid M.
    Flint, Robert B.
    Reiss, Irwin K. M.
    Simons, Sinno H. P.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2021, 34 (15) : 2411 - 2417
  • [26] Patent ductus arteriosus (PDA) and pulmonary morbidity: can early targeted pharmacologic PDA treatment decrease the risk of bronchopulmonary dysplasia?
    Clyman, Ronald I.
    Hills, Nancy K.
    SEMINARS IN PERINATOLOGY, 2023, 47 (02)
  • [27] Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus
    Sallmon, Hannes
    Koehne, Petra
    Hansmann, Georg
    CLINICS IN PERINATOLOGY, 2016, 43 (01) : 113 - 129
  • [28] Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus
    Al-lawama, Manar
    Alammori, Iyad
    Abdelghani, Tariq
    Badran, Eman
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (02) : 811 - 818
  • [29] Echocardiography as a guide for patent ductus arteriosus ibuprofen treatment and efficacy prediction
    Desandes, Roxane
    Jellimann, Jean-Marc
    Rouabah, Mahmoud
    Haddad, Fouad
    Desandes, Emmanuel
    Boubred, Farid
    Semama, Denis S.
    Vieux, Rachel
    Hascoet, Jean-Michel
    PEDIATRIC CRITICAL CARE MEDICINE, 2012, 13 (03) : 324 - 327
  • [30] Patent Ductus Arteriosus Therapy: Impact on Neonatal and 18-Month Outcome
    Madan, Juliette C.
    Kendrick, Douglas
    Hagadorn, James I.
    Frantz, Ivan D., III
    PEDIATRICS, 2009, 123 (02) : 674 - 681